Cellular immunotherapy with T cells genetically engineered to express chimeric antigen receptors (CARs)is emerging as a promising new treatment modality for an increasing range of haematological cancers. As adoptive T-cell therapies become more widely used, recognition of their unique toxicities is of the utmost importance; the majority of these events can be classified as mild or moderate, but severe and life-threatening complications requiring ICU admission also occur. The two most commonly observed toxicities with CAR-T-cell therapies are cytokine-release syndrome (CRS), characterized by high fever, hypotension, hypoxia, and/or multiorgan toxicity; and an immune effector cell-associated neurotoxicity syndrome (ICANS) may manifest as delirium, encephalopathy, aphasia, lethargy, difficulty concentrating, agitation, tremor, seizures and, rarely, cerebral oedema. Rare cases of fulminant haemophagocytic lymphohistio-cytosis (HLH) and immune-mediated multiorgan failure, have also been reported.

We would like to invite you to support the first CAR-T in ICU meeting, where we will focus on:

  • The pathophysiology
  • Symptoms associated with treatment
  • Management of side effects in ICU
  • Experience from different European centres
  • Recognition of deteriorating patients
  • Admission thresholds
  • Initial ICU management
  • Escalating management of toxicities